Analysis of the causes of switching first-line antiretroviral agents in treatmentnaive HIV/AIDS patients in Shanghai

ZHENG Yufang,LIU Li,ZHANG Renfang,SHEN Yinzhong,QI Tangkai,WANG Jiangrong,LU Hongzhou

DOI: https://doi.org/10.3969/j.issn.1009-7708.2012.01.002

2012-01-01

Abstract:Objective To compare the tolerability of a variety of antiretroviral agents by analyzing the time to, cause and frequency of treatment switch in treatment-naïve HIV/AIDS patients receiving national free antiretroviral treatment in Shanghai. Methods This retrospective analysis was conducted in 1 154 patients receiving anti-retroviral therapy (ART) to compare the most common causes and frequency of switching each antiretroviral agent at different time period since the start of ART. Results Within 3 months since the initiation of ART, the most common causes of treatment switch included: nevirapine due to severe rashes, efavirenz due to serious rashes and zidovudine due to ANC < 0.75×10 9/L. Beyond 3 months of treatment, more patients discontinued zidovudine due to severe anemia, or switched off nevirapine due to liver toxicity. After ART for 1 year, treatment switch was mostly due to d4T-induced peripheral neuropathy, fat redistribution, dyslipidemia and treatment failure. A total of 352 episodes of treatment switch occurred for various reasons. There were 302 (26.17%) episodes of serious adverse drug reactions. Treatment failure was documented in 50 (4.33%) patients. After d4T treatment for 1 year, the frequency of treatment switch due to dyslipidemia, fat redistribution, and treatment failure increased. Zidovudine switch-off was mainly due to severe bone marrow suppression, mostly within 6 months after ART. Switch treatment of efavirenz was infrequent. Discontinuation of nevirapine was mainly due to serious rash and Grade 3 hepatotoxicity; mostly within a month after ART. Conclusions The type and frequency of adverse drug reaction varies with the duration of ART. Some adverse drug reactions occur in a wide range of time period. Adverse drug reaction is still a key factor affecting the compliance and efficacy of ART.